If left untreated, patients with Evans syndrome have periods of exacerbation. Common complications of Evans syndrome include thrombocytopenia and autoimmune haemolytic anaemia. Depending on the extent of the tumor at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as good.

• The disease has a chronic course with periods of exacerbation and remissions. The remissions are induced by treatment.

• Thrombocytopenia
• Autoimmune haemolytic anaemia

• The prognosis depends on the patient’s response to treatment. Spontaneous remissions of each of the individual component conditions have been reported. If the child responds well to the treatment and the levels of platelets and red blood cells increase, the child can expect to live a normal life. Medications will be needed life long, and laboratory tests will need to be constantly monitored to detect any abnormal changes so that treatment can be adjusted.
• In more serious cases Evans syndrome can reduce life span and may be seriously life threatening.
• Evan’s Syndrome is rare and has a reported mortality rate of just under 18%.
• It has been observed that there is a risk of developing other autoimmune problems and hypogammaglobulinemia,^[1] with recent research finding that 58% of children with Evans syndrome have CD4-/CD8- T cells which is a strong predictor for having autoimmune lymphoproliferative syndrome.^[2]